Lenacapavir is a long-acting injectable form of PrEP that blocks HIV entry and replication. It is administered at six-month intervals and is the longest-acting injectable produced to date. In late-stage trials the drug cut infections by 96% among diverse groups, and in the PURPOSE 2 study only two people out of more than 2,000 became infected. The earlier PURPOSE 1 study found no cisgender women contracted HIV while using the drug.
Gilead is seeking regulatory approval in several African countries and plans to begin processes by the end of 2024 in 18 low- and middle-income countries. Experts including Hasina Subedar and Colleen Kelley say affordability and the ability to reach people who struggle with daily pills will shape impact.
Gilead has licensing agreements with six generic manufacturers to make generic versions for 120 resource-limited countries and says it will supply the product at no profit until generics can meet demand. Advocates warn of practical challenges such as building reliable supply chains, ensuring people return for injections every six months, and offering community choices. Countries like Zambia and Kenya are expected to be early adopters and tests of real-world impact.
Difficult words
- administer — to give a drug or treatment to someoneadministered
- replication — process of a virus making more copies
- trial — a test of a drug with peopletrials
- affordability — whether people can pay for a medicine
- agreement — a formal deal between two organisationsagreements
- generic — a product not made by the original company
- supply chain — system that moves goods to where neededsupply chains
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How could six-month injections help people who have trouble taking daily pills?
- What problems might health systems face when they build reliable supply chains for injections?
- If you lived in a country starting this program, what reasons would make you try or refuse the injection?
Related articles
Joha rice may help prevent diabetes and protect the heart
Researchers in India report that Joha, a scented short-grain rice from the northeast, showed benefits in lab and rat studies against type 2 diabetes and heart disease. Tests found healthy fats, antioxidants and improved insulin response.
Few new antibiotics for children amid rising resistance
Global experts warn that few child-friendly antibiotics are being developed while antimicrobial resistance already causes millions of deaths. A 2026 Benchmark finds fewer drugs in company pipelines and a shortage of medicines for under-five children.
Contrast test can show early vision problems in older adults
A new study links a Pelli-Robson contrast sensitivity test to everyday vision difficulties for older adults. The test finds problems that routine high‑contrast eye charts can miss and may help clinicians detect treatable early changes.
Some low-cost glucometers read newborn glucose accurately
A Rice360 study tested commonly available point-of-care glucometers in the lab to see if low-cost models can measure newborn glucose safely. Several inexpensive meters gave reliable readings at neonatal ranges, offering options for low-resource hospitals.